Intellectual PropertyFROXIMUN AG is the owner of several trademark protection rights for the trademarks used and application patents for MANC. National and international utility patents refer to the areas of application for the basic substance clinoptilolite in the pharmaceutical field. These are specifically protective patents for the application of an activated and modified clinoptilolite as a medical device used in disorders of the metabolic organs, particularly the liver, kidneys and pancreas,
- The removal of lead, mercury and ammonia from the digestive tract in humans and animals,
- The removal of mercury and amalgam from the tooth and jaw area and
- The binding of exogenous histamine in the digestive tract as well as in external wounds in humans and animals.
Research & DevelopmentFROXIMUN research focuses on acquiring knowledge of why certain chronic and non-chronic illnesses can be alleviated and/or treated with FROXIMUN medical devices. The objective is to research how such human illnesses can be avoided via the preventive use of FROXIMUN medical devices and reducing the risk of an illness via such preventive use. Another primary objective is to integrate the knowledge acquired immediately in the required forms of treatment and possibly initiating a paradigm shift.
"The main goal in life is not to know but to act.”